- Levy SB, (1992) The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. New York, Plenum, 279 pp. [Google Scholar]
- Roberts JA, Taccone FS, Lipman J, (2016) Understanding PK-PD. Intensive Care Med 42: 1797–1800 [CrossRef] [PubMed] [Google Scholar]
- Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ, (2017) Multicenter observational study of Ceftaroline Fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 61: pii: e02015-16 [Google Scholar]
- Castón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J, (2017) Salvage therapy with ceftolozane-tazobactam for multidrug resistant P. aeruginosa infections. Antimicrob Agents Chemother 61: pii: e02136-16 [Google Scholar]
- Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH, (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63: 1615–1618 [CrossRef] [PubMed] [Google Scholar]
- Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y, (2017) Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 24: pii: e01964-16 [Google Scholar]
- Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH, (2017) Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother 21: pii: AAC.02534-16 [Google Scholar]
- Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VGJr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA, (2017) Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother [in press] [Google Scholar]
- Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos ML, (2014) Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20: 862–872 [CrossRef] [PubMed] [Google Scholar]
- Livermore D, Mushtaq S, Woodford N, (2016) In vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3840–3844 [CrossRef] [PubMed] [Google Scholar]
Accès gratuit
Editorial
| Numéro |
Méd. Intensive Réa.
Volume 26, Numéro 3, Mai 2017
Infectieux
|
|
|---|---|---|
| Page(s) | 164 - 166 | |
| Section | Éditorial / Editorial | |
| DOI | https://doi.org/10.1007/s13546-017-1272-1 | |
| Publié en ligne | 21 mars 2017 | |
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.